Jul 26, 2006|
Pharma: The DPCO effect!
Government policies affect the economy and financial markets in a big way. The effect of politics has been apparent in the energy sector wherein products such as kerosene, petrol and LPG have been subsidised despite rising crude prices, consequently causing oil-marketing companies to bleed. In the pharma sector, it is the DPCO (drug price control order), which as been the bane of the industry since 1979. While the government has not officially announced the new and much-debated DPCO policy, here are the likely implications of the same in the event that it gets passed.
Likely implications of the policy
'Accessibility' is the key: The new policy proposes to bring 354 essential medicines under price control as against the 74 drugs under price control at present. Should the policy go through, a large part of the industry turnover is likely to be impacted by the effect of price control. One of the main reasons cited by the ministry for increasing the span of control is to make cheaper medicines more 'accessible' to the population. That said, despite the fact that drug prices in India are one of the lowest in the world, drugs still remain inaccessible to around 70% of the population (as per our interaction with a leading pharma major). This highlights the fact that it is the 'accessibility' issue that needs to be addressed by the government and not the 'affordability' issue.
Impact on growth prospects: The proposed policy is expected to affect profitability of the entire pharma industry and not just a few companies. For instance, domestic pharma companies have been ploughing back profits earned from the domestic and international markets into their R&D programme, which has picked up pace since the introduction of the product patent law in the country. This means that significant reduction in prices will hamper the R&D efforts to a certain extent. That said, international focus of the domestic companies will provide some cushion to overall earnings and profitability. The impact of this law is likely to be more pronounced for MNC pharma majors, whose focus is largely on the domestic markets and do not have export revenues to insulate themselves from the impact of the policy.
Threat of spurious drugs: The industry over the years has had to contend with the presence of spurious and counterfeit drugs with this practice being more rampant in the North and a part of the East. While the government has been reasonably successful in curbing this practice, it is likely to rear its ugly head in the event that this new policy becomes effective. Another problem that the industry could face is the shortage in availability of drugs. This is because companies may choose to stop the manufacturing of those drugs, where margins get severely impacted.
Since the new DPCO law has not been passed, it is difficult to assess the exact impact of the same on the financial numbers of pharma companies. The industry has been making representations to the government highlighting the negative impact of the policy. That said, whatever the result, it is imperative that the issue gets resolved as soon as possible. While price control is not a desirable option for the industry, the government can monitor the prices to make sure that they do not rise steeply. This practice is followed in Europe, where the prices of branded drugs on an average tend to be around 20% lower than the prices in the US. Investors should note that excluding the DPCO, growth is visible in most of the pharma companies under our coverage. That said, valuations will be the key and we advise investors to adopt a stock-specific investment strategy.
More Views on News
Jun 10, 2017
Forty Indian investing gurus, as worthy of imitation as the legendary Peter Lynch, can help you get rich in the stock market.
Aug 16, 2017
All across the country, the old gods become devils. New, gluten-free gods take their places...
Aug 16, 2017
And what it has in common with beating the stock market too.
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Aug 14, 2017
Last week's correction is making a number of Super Investor stocks look a lot more attractive...
More Views on News
Aug 7, 2017
The data tells us quite a different story from the one the government is trying to project.
Aug 4, 2017
The small-cap space is full of small players that are clear proxies to great growth stories and Indian megatrends.
Aug 8, 2017
Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 7, 2017
Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407